Aashka Hospitals Limited (AASHKA) Fair Value & Analysis
Healthcare · IN · Market cap ₹1.9B
Fair value as of: Jul 5, 2026
From 22 valuation models · updated today
Share price +8.4% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹59.00 – ₹103.50 · fair‑value band ₹17.69 – ₹30.32 · the ₹81.25 price screens above the ₹23.70 fair value. As of Jul 5, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Aashka Hospitals Limited (AASHKA) currently trades at ₹81.25, while our model-based Fair Value estimate is ₹23.70 — implying the stock looks roughly 70.8% overvalued today. We read business quality at 56/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Aashka Hospitals Limited generated revenue of ₹230M at a net margin of 14.5%. Revenue grew 22.2% year over year. It earns a return on equity of 3.3%. Net debt stands at ₹39.1M. Fundamentals as of Jul 5, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.
About the company
Aashka Hospitals Limited operates multi-disciplinary private hospitals, clinic, and pharmacies India. The company provides ophthalmology, gastroenterology and gastroentero surgery, pulmonology, neurosurgery, pain management, pediatrics and neonatology, physiotherapy and rehabilitation, obstetrics and gynecology, dentistry, cardiothoracic and vascular surgery, critical care, cardiology, anesthesiology, dermatology and cosmetology, ENT, emergency and trauma care, endoscopy services. It offers general and laparoscopic surgery, interventional radiology, internal medicine, geriatrics, medical and haemato oncology, nephrology and dialysis, neurology, orthopedics and join replacement, plastic and reconstructive surgery, psychiatry, radiology, surgical oncology, and urology services. The company was incorporated in 2012 and is based in Gandhinagar, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Aashka Hospitals Limited reported revenue of ₹230M in FY2026 versus ₹397M in FY2022, a compound −12.8%/yr. Reported net income was ₹33.4M in FY2026, compounding +9.0%/yr from FY2022.
Is AASHKA fairly valued? → Check now
Similar stocks
6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 5, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc H1CA34 | R$95.75 | R$123.65 | +29% |
| Fresenius SE FSNUY | $11.30 | $8.61 | -24% |
| Q0F Q0F | 2.76 SGD | 1.28 SGD | -54% |
| 5225 5225 | 8.71 MYR | 4.87 MYR | -44% |
| IHHHF IHHHF | $1.71 | $1.17 | -32% |
| Rede D'Or São Luiz S.A RDOR3 | R$32.76 | R$30.33 | -7% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Aashka Hospitals Limited (AASHKA) undervalued?
What is the fair value of AASHKA?
What is the quality score of AASHKA?
What is the revenue of Aashka Hospitals Limited (AASHKA)?
What is the net profit margin of AASHKA?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.